Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated 30 June 2016 (the "**Prospectus**") issued by Vincent Medical Holdings Limited (the "**Company**").

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus for detailed information about the Hong Kong Public Offering and the International Placing described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act 1933, as amended or supplemented from time to time (the "U.S. Securities Act"). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States as offshore transactions in accordance with Regulation S under the U.S. Securities Act.

In connection with the Global Offering, BOSC International Company Limited, as stabilising manager (the "Stabilising Manager"), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilising or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it, to conduct any such stabilising action, which, if commenced, will be done at the sole and absolute discretion of the Stabilising Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilising activity is required to be brought to an end on the 30th day after the last date for lodging applications under the Hong Kong Public Offering. Such stabilisation action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong).

Potential investors should be aware that stabilising actions cannot be taken to support the price of the Shares for longer than the stabilisation period which will begin on the Listing Date and expire on Friday, 5 August 2016, being the 30th day after the last date for lodging applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken and demand for the Shares and the price of the Shares could fall.



永勝醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	:	127,600,000 Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	12,760,000 Shares (subject to adjustment and including 1,276,000 Employee Reserved Shares)
Number of International Placing Shares	:	114,840,000 Shares (subject to adjustment and the Over-allotment Option)
Offer Price	•	not more than HK\$1.25 per Offer Share (payable in full on application in Hong Kong dollars, subject to refund, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) and expected to be not less than HK\$1.00 per Offer Share
Nominal Value	:	HK\$0.01 per Share
Stock Code	:	1612

Sole Sponsor and Sole Global Coordinator



Joint Bookrunners

Joint Lead Managers









CIMB CROSBY





Application has been made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares in issue and to be issued as described in the Prospectus (including (i) the Shares in issue; (ii) the Shares to be issued pursuant to the Capitalisation Issue and the Global Offering (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option); and (iii) the Shares which may be issued pursuant to the exercise of the options granted under the Share Option Schemes). Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, 13 July 2016. In the event the Over-allotment Option is exercised, an announcement will be made by the Company on the Company's website at <u>www.vincentmedical.com</u> and the Stock Exchange's website at <u>www.hkexnews.hk</u>.

The Global Offering comprises: (1) the Hong Kong Public Offering of 12,760,000 Offer Shares, representing 10% of the total Offer Shares initially available under the Global Offering (subject to adjustment and including 1,276,000 Employee Reserved Shares); and (2) the International Placing of 114,840,000 Offer Shares, representing 90% of the total Offer Shares initially available under the Global Offering (subject to adjustment and the Over-allotment Option). The allocation of the Offer Shares between the Hong Kong Public Offering and the International Placing will be subject to adjustment as described in the section headed "Structure of the Global Offering" in the Prospectus.

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, which is exercisable by the Stabilising Manager on behalf of the International Underwriters, to require the Company to allot and issue up to 19,140,000 additional Offer Shares, representing 15% of the number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Placing, if any.

Subject to the granting of the approval for listing of, and permission to deal in, the Shares on the Main Board and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or on any other date as determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$1.25 per Offer Share and is currently expected to be not less than HK\$1.00 per Offer Share, unless otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$1.25 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$1.25 per Offer Share.

Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and the Application Forms and the designated website (www.hkeipo.hk) for the HK eIPO White Form. Applicants who would like to have the allotted Hong Kong Offer Shares registered in their own names should either (i) complete and sign the WHITE Application Forms, or (ii) submit applications online through the designated website of the HK eIPO White Form Service Provider at www.hkeipo.hk under the HK eIPO White Form service. Applicants who would like to have the allotted Hong Kong Offer Shares registered in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either (i) complete and sign the YELLOW Application Forms, or (ii) give electronic application instructions to HKSCC via CCASS. Applicants who are Eligible Employees who wish to apply for Employee Reserved Shares under the Employee Preferential Offering should complete and sign the PINK Application Form.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be collected during normal business hours from 9:00 a.m. on Thursday, 30 June 2016, until 12:00 noon on Wednesday, 6 July 2016 from

(i) any of the following offices of the Joint Bookrunners:

BOSC International Company Limited	34 th Floor, Champion Tower 3 Garden Road, Central Hong Kong
Crosby Securities Limited	5 th Floor AXA Centre 151 Gloucester Road Wan Chai Hong Kong
Shenwan Hongyuan Capital (H.K.) Limited	Level 19 28 Hennessy Road Hong Kong

(ii) any of the following branches of the receiving bank:

Bank of China (Hong Kong) Limited

	Branch name	Address
Hong Kong Island	Bank of China Tower Branch	3/F, 1 Garden Road
	Gilman Street Branch	136 Des Voeux Road Central
	409 Hennessy Road Branch	409–415 Hennessy Road, Wan Chai
Kowloon	Prince Edward Road West (Mong Kok) Branch	116–118 Prince Edward Road West, Mong Kok, Kowloon
	To Kwa Wan Branch	80N To Kwa Wan Road, To Kwa Wan
	Chuk Yuen Estate Branch	Shop S1, Chuk Yuen Shopping Centre, Chuk Yuen South Estate
	Tseung Kwan O Plaza Branch	Shop 112–125, Level 1, Tseung Kwan O Plaza, Tseung Kwan O
New Territories	Fo Tan Branch	No. 2, 1/F Shatin Galleria, 18–24 Shan Mei Street, Fo Tan
	Yuen Long (Hang Fat Mansion) Branch	8-18 Castle Peak Road, Yuen Long
	Tai Po Plaza Branch	Unit 4, Level 1 Tai Po Plaza, 1 On Tai Road, Tai Po

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be collected during normal business hours from 9:00 a.m. on Thursday, 30 June 2016 until 12:00 noon on Wednesday, 6 July 2016 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have such Application Forms and the Prospectus available.

The WHITE or YELLOW Application Form completed in all respects in accordance with the instructions printed thereon, together with a cheque or a banker's cashier order marked payable to "Bank of China (Hong Kong) Nominees Limited — Vincent Medical Public Offer" attached and securely stapled, should be deposited in the special collection boxes provided at any of the branches of the receiving bank listed above, at the following times:

Thursday, 30 June 2016 — 9:00 a.m. to 5:00 p.m. Saturday, 2 July 2016 — 9:00 a.m. to 1:00 p.m. Monday, 4 July 2016 — 9:00 a.m. to 5:00 p.m. Tuesday, 5 July 2016 — 9:00 a.m. to 5:00 p.m. Wednesday, 6 July 2016 — 9:00 a.m. to 12:00 noon Applicants applying by **HK eIPO White Form** may submit applications through the **HK eIPO White Form** service at <u>www.hkeipo.hk</u> from 9:00 a.m. on Thursday, 30 June 2016 until 11:30 a.m. on Wednesday, 6 July 2016 and the latest time for completing full payment of application monies in respect of such applications will be 12:00 noon on Wednesday, 6 July 2016 or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares and Employee Reserved Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

Time for Inputting Electronic Application Instructions

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Thursday, 30 June 2016 — 9:00 a.m. to 8:30 p.m.⁽¹⁾ Saturday, 2 July 2016 — 8:00 a.m. to 1:00 p.m.⁽¹⁾ Monday, 4 July 2016 — 8:00 a.m. to 8:30 p.m.⁽¹⁾ Tuesday, 5 July 2016 — 8:00 a.m. to 8:30 p.m.⁽¹⁾ Wednesday, 6 July 2016 — 8:00 a.m.⁽¹⁾ to 12:00 noon

Note:

(1) These times are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/ Custodian Participants.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Thursday, 30 June 2016 until 12:00 noon on Wednesday, 6 July 2016 (24 hours daily, except on the last application day).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Wednesday, 6 July 2016 or such later application day or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares and Employee Reserved Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

Copies of the Prospectus, together with the **PINK** Application Forms can be collected by Eligible Employees from the Company's head office at Flat B2, 7th Floor, Phase 2, Hang Fung Industrial Building, 2G Hok Yuen Street, Hung Hom, Hong Kong during normal business hours from 9:00 a.m. on Thursday, 30 June 2016 until 12:00 noon on Tuesday, 5 July 2016. Electronic copies of the **PINK** Application Form and the Prospectus can be viewed from the Company's website (**www.vincentmedical.com**) and the Stock Exchange's website (**www.hkexnews.hk**). Completed **PINK** Application Forms, together with a cheque attached and marked payable to "**Bank of China** (**Hong Kong**) **Nominees Limited — Vincent Medical Public Offer**" for the payment must be returned to the Company's head office at Flat B2, 7th Floor, Phase 2, Hang Fung Industrial Building, 2G Hok Yuen Street, Hung Hom, Hong Kong by 12:00 noon on Tuesday, 5 July 2016.

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares and Employee Reserved Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish the announcement on the final Offer Price, the level of indication of interest in the International Placing, the level of applications in the Hong Kong Public Offering and the Employee Preferential Offering and the basis of allocation of the Hong Kong Offer Shares on Tuesday, 12 July 2016 in (i) the South China Morning Post (in English); (ii) the Hong Kong Economic Times (in Chinese); (iii) on the Stock Exchange's website (<u>www.hkexnews.hk</u>) and (iv) on the Company's website (<u>www.vincentmedical.com</u>). The results of allocations and the identification document number, where appropriate, of successful applicants under the Hong Kong Public Offering and the Employee Preferential Offering will be available through a variety of channels from Tuesday, 12 July 2016 as described in the section headed "How to Apply for Hong Kong Offer Shares and Employee Reserved Shares — 11. Publication of Results" in the Prospectus, including the website of the Stock Exchange at <u>www.hkexnews.hk</u> and on the Company's website at <u>www.vincentmedical.com</u>.

The Company will not issue temporary documents of title. Share certificates will only become valid at 8:00 a.m. on Wednesday, 13 July 2016 provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting" in the Prospectus has not been exercised. No receipt will be issued for sums paid on application. Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, 13 July 2016. The Shares will be traded in board lots of 2,000 Shares each. The stock code of the Shares is 1612.

On behalf of the Board of Directors of Vincent Medical Holdings Limited Choi Man Shing Chairman and Executive Director

Hong Kong, 30 June 2016

As at the date of this announcement, the board of Directors of the Company comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Ms. Liu Pui Ching, Mr. Amir Gal Or and Mr. Poon Lai Yin Michael (alternate to Mr. Amir Gal Or) as non-executive Directors, and Mr. Chan Ling Ming, Mr. Mok Kwok Cheung Rupert and Mr. Au Yu Chiu Steven as independent non-executive Directors.

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).